Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Abhishek Shankar is active.

Publication


Featured researches published by Abhishek Shankar.


Asian Pacific Journal of Cancer Prevention | 2015

Level of Awareness of Cervical and Breast Cancer Risk Factors and Safe Practices among College Teachers of Different States in India: Do Awareness Programmes Have an Impact on Adoption of Safe Practices?

Abhishek Shankar; Goura Kishor Rath; Shubham Roy; Abhidha Malik; Ruchir Bhandari; Kunal Kishor; Keshav Barnwal; Sneha Upadyaya; Vivek Srivastava; Rajan Singh

BACKGROUND Breast and cervical cancers are the most common causes of cancer mortality among women in India, but actually they are largely preventable diseases. Although early detection is the only way to reduce morbidity and mortality, there are limited data on breast and cervical cancer knowledge, safe practices and attitudes of teachers in India. The purpose of this study is to assess the level of awareness and impact of awareness programs in adoption of safe practices in prevention and early detection. MATERIALS AND METHODS This assessment was part of a pink chain campaign on cancer awareness. During cancer awareness events in 2011 at various women colleges in different parts in India, a pre-test related to cervical cancer and breast cancer was followed by an awareness program. Post-tests using the same questionnaire were conducted at the end of the interactive session, at 6 months and 1 year. RESULTS A total of 156 out of 182 teachers participated in the study (overall response rate was 85.7 %). Mean age of the study population was 42.4 years (range- 28-59 yrs). There was a significant increase in level of knowledge regarding cervical and breast cancer at 6 months and this was sustained at 1 year. Adoption of breast self examination (BSE) was significantly more frequent in comparison to CBE, mammography and the Pap test. Magazines and newspapers were sources for knowledge regarding screening tests for breast cancer in more than 60% of teachers where as more than 75% were educated by doctors regarding the Pap test. Post awareness at 6 months and 1 year, there was a significant change in alcohol and smoking habits. Major reasons for not doing screening test were found to be ignorance (50%), lethargic attitude (44.8%) and lack of time (34.6%). CONCLUSIONS Level of knowledge of breast cancer risk factors, symptoms and screening methods was high as compared to cervical cancer. There was a significant increase in level of knowledge regarding cervical and breast cancer at 6 months and this was sustained at 1 year. Adoption of BSE was significantly greater in comparison to CBE, mammography and the Pap test. To inculcate safe practices in lifestyle of people, awareness programmes such as pink chain campaign should be conducted more widely and frequently.


Asian Pacific Journal of Cancer Prevention | 2016

Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?

Abhidha Malik; Pamela Alice Jeyaraj; Rajneesh Calton; Bharti Uppal; Preety Negi; Abhishek Shankar; Jaineet Patil; Manmohan Kishan Mahajan

BACKGROUND The early detection of anthracycline- induced cardiotoxicity is very important since it might be useful in prevention of cardiac decompensation. This study was designed with the intent of assessing the usefulness of cardiac troponin T (cTnT) and NT- Pro BNP estimation in early prediction of anthracycline induced cardiotoxicity. MATERIALS AND METHODS In this prospective study histologically proven breast cancer patients who were scheduled to receive anthracycline containing combination chemotherapy as a part of multimodality treatment were enrolled. Baseline cardiac evaluation was performed by echocardiography (ECHO) and biomarkers like cardiac troponin T (cTnT) and N terminal- pro brain natriuretic peptide (NT- Pro BNP). All patients underwent cTnT and NT- Pro BNP estimation within 24 hours of each cycle of chemotherapy and were followed up after 6 months of initiation of chemotherapy. Any changes in follow up ECHO were compared to ECHO at baseline and cTnT and NT- Pro BNP levels after each cycle of anthracycline-based chemotherapy. RESULTS Initial data were obtained for 33 patients. Mean change in left ventricular diastolic diameter (LVDD) within 6 months was 0.154± 0 .433 cms (p value=0.049). Seven out of 33 patients had an increase in biomarker cTnT levels (p value=0.5). A significant change in baseline and follow up LVDD was observed in patients with raised cTnT levels (p value=0.026) whereas no change was seen in ejection fraction (EF) and left atrial diameters (LAD) within 6 months of chemotherapy. NT- Pro BNP levels increased in significant number of patients (p value ≤0.0001) but no statistically significant change was observed in the ECHO parameters within 6 months. CONCLUSIONS Functional monitoring is a poorly effective method in early estimation of anthracycline induced cardiac dysfunction. Estimation of biomarkers after chemotherapy may allow stratification of patients in various risk groups, thereby opening window for interventional strategies in order to prevent permanent damage to the myocardium.


Asian Pacific Journal of Cancer Prevention | 2015

Passive Smoking and Breast Cancer - a Suspicious Link

Abhidha Malik; Pamela Alice Jeyaraj; Abhishek Shankar; Goura K. Rath; Sandip Mukhopadhyay; Vineet Kumar Kamal

BACKGROUND Breast cancer is the most common malignancy of women in the world. The disease is caused by infectious and non-infectious, environmental and lifestyle factors. Tobacco smoke has been one of the most widely studied environmental factors with possible relevance to breast cancer. The purpose of this study was to assess the impact of tobacco smoking in breast cancer patients in a hospital based cohort and to establish prognostic implications if any. MATERIALS AND METHODS A retrospective audit of 100 women with pathological diagnosis of invasive breast cancer was included in this study. The verbal questionnaire elicited information on current and previous history of exposure to smoking in addition to active smoking. All analyses were adjusted for potential confounders, including stage at presentation, alcohol intake, hormonal replacement therapy, oral contraceptive intake, obesity and menopausal status. RESULTS The mean age at presentation of breast cancer was 51.4 ± 10.86 years. Mean age of presentation was 53.1±11.5 and 45.7±11.9 years in never smokers and passive smokers, respectively. Age at presentation varied widely in patients exposed to tobacco smoke for >10 years in childhood from 40.3± 12.0 years to 47.7± 13.9 in patients exposed for > 20 years as adults. Among passive smokers, 60.9% were premenopausal and 39.1% of patients were postmenopausal. In never smokers, 71.4% were post menopausal. Expression of receptors in non-smokers vs passive smokers was comparable with no significant differences. Metastatic potential in lung parenchyma was slightly elevated in passive smokers as compared to never smokers although statistically non-significant. CONCLUSIONS An inverse relationship exists between the intensity and duration of smoking and the age at presentation and poor prognostic factors. The results strongly suggest efforts should be taken to prevent smoking, encourage quitting and restrict exposure to second hand smoke in India.


Asian Pacific Journal of Cancer Prevention | 2015

Contralateral breast cancer: a clinico-pathological study of second primaries in opposite breasts after treatment of breast malignancy.

Abhishek Shankar; Shubham Roy; Abhidha Malik; Vineet Kumar Kamal; Ruchir Bhandari; Kunal Kishor; Manmohan Kishan Mahajan; Jaineet Sachdev; Pamela Alice Jeyaraj; Goura Kishor Rath

BACKGROUND Breast cancer is by far the most frequent cancer of women (23 % of all cancers), ranking second overall when both sexes are considered together. Contralateral breast cancer (CBC) is becoming an important public health issue because of the increased incidence of primary breast cancer and improved survival. The present communication concerns a study to evaluate the role of various clinico-pathological factors on the occurrence of contralateral breast cancer. MATERIALS AND METHODS A detailed analysis was carried out with respect to age, menopausal status, family history, disease stage, surgery performed, histopathology, hormone receptor status, and use of chemotherapy or hormonal therapy. The diagnosis of CBC was confirmed on histopathology report. Relative risk with 95%CI was calculated for different risk factors of contralateral breast cancer development. RESULTS CBC was found in 24 (4.5%) out of 532 patients. Mean age of presentation was 43.2 years. Family history of breast cancer was found in 37.5% of the patients. There was statistically significant higher rate (83.3%) of CBC in patients in age group of 20-40 years with RR=11.3 (95% CI: 1.4, 89.4, p=0.006) seen in 20-30 years and RR=10.8 (95% CI:1.5-79.6, p=0.002) in 30-40 years as compared to older age of 60-70 years. Risk of development was higher in premenopausal women (RR=8.6, 95% CI: 3.5-21.3, p≤0.001). Women with family history of breast cancer had highest rate (20.9%) of CBC (RR=5.4, 95% CI: 2.5-11.6, p≤0.001). Use of hormonal therapy in hormone receptor positive patients was protective factor in occurrence of CBC but not significant (RR=0.7, 95% CI: 0.3-1.5, p=0.333). CONCLUSIONS Younger age, premenopausal status, and presence of family history were found to be significant risk factors for the development of CBC. Use of hormonal therapy in hormone receptor positive patients might be protective against occurrence of CBC but did not reach significance.


Asian Pacific Journal of Cancer Prevention | 2017

Current Trends in Management of Oral Mucositis in Cancer Treatment

Abhishek Shankar; Shubham Roy; Menal Bhandari; Goura K. Rath; Aalekhya Sharma Biswas; Ravi Kanodia; Narayan Adhikari; Rashika Sachan

Oral Mucositis (OM) is among the most common and dreaded toxicities of cancer therapy. It occurs in almost all patients who receive radiation therapy in which areas of oral and oropharyngeal mucosa are included in the treatment field. With the advent of chemotherapy in 1940 and its extended clinical legacy, it is only within the past two decade or so that mucositis’ complex pathobiology has become fully appreciated. There are still many unanswered questions about the risk factors for developing OM, but historically, risk factors have been attributed to both therapy and patient m characteristics. One thing that has been consistent from the initial descriptions of its clinical manifestations has been the frustration on the part of clinicians and patients with the scarcity of therapeutic options to prevent or treat the condition, or effectively ameliorate the symptoms. Clinicians, researchers and those involved in oral and periodontal medicine should join hand in hand in persuit of understanding and developing treatment strategies for treatment of inflammatory conditions like OM in oncology. This will lead to development of effective treatments and reducing the burden of OM and other inflammatory conditions in oncology.


Asian Pacific Journal of Cancer Prevention | 2015

Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Patients.

Abhishek Shankar; Shubham Roy; Abhidha Malik; Pramod Kumar Julka; Goura Kishor Rath

The supportive care of patients receiving antineoplastic treatment has dramatically improved over the past few years and development of effective measures to prevent nausea and vomiting after chemotherapy serves as one of the most important examples of this progress. A patient who starts cancer treatment with chemotherapy lists chemotherapy-induced nausea and vomiting as among their greatest fears. Inadequately controlled emesis impairs functional activity and quality of life, increases the use of health care resources, and may occasionally compromise adherence to treatment. New insights into the pathophysiology of chemotherapy-induced nausea and vomiting, a better understanding of the risk factors for these effects, and the availability of new antiemetic agents have all contributed to substantial improvements in emetic control. This review focuses on current understanding of chemotherapy-induced nausea and vomiting and the status of pharmacological interventions for their prevention and treatment.


Asian Pacific Journal of Cancer Prevention | 2015

Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.

Abhishek Shankar; Shubham Roy; Goura Kishor Rath; Pramod Kumar Julka; Vineet Kumar Kamal; Abhidha Malik; Jaineet Patil; Pamela Alice Jeyaraj; Manmohan Kishan Mahajan

BACKGROUND Preclinical studies have shown that the combination of an aromatase inhibitor (AI) and capecitabine in estrogen receptor (ER)-positive cell lines enhance antitumor efficacy. This retrospective analysis of a group of patients with metastatic breast cancer (MBC) evaluated the efficacy and safety of combined AI with capecitabine. MATERIALS AND METHODS Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy. RESULTS Of 72 patients evaluated, 31 received the combination treatment, 22 AI and 19 capecitabine. The combination was used in 20 patients as first-line and 11 as second-line treatment. Mean age was 46.2 years with a range of 28-72 years. At the time of progression, 97% had a performance status of <2 and 55% had visceral disease. No significant difference was observed between the three groups according to clinical and pathological features. Mean follow up was 38 months with a range of 16-66 months. The median PFS of first-line treatment was significantly better for the combination (PFS 21 months vs 8.0 months for capecitabine and 15.0 months for AI). For second-line treatment, the PFS was longer in the combination compared with capecitabine and Al groups (18 months vs. 5.0 months vs. 11.0 months, respectively). Median 2 year and 5 year survival did not show any significant differences among combination and monotherapy groups. The most common adverse events for the combination group were grade 1 and 2 hand-for syndrome (69%), grade 1 fatigue (64%) and grade 1 diarrhoea (29%). Three grade 3 hand-foot syndrome events were reported. CONCLUSIONS Combination treatment with capecitabine and AI used as a first line or second line treatment was safe with much lowered toxicity. Prospective randomized clinical trials should evaluate the use of combination therapy in advanced breast cancer to confirm these findings.


Journal of Global Oncology | 2018

Impact of Cancer Awareness Drive on Generating Awareness of and Improving Screening for Cervical Cancer: A Study Among Schoolteachers in India

Abhishek Shankar; Shubham Roy; Goura Kishor Rath; Abhijit Chakraborty; Vineet Kumar Kamal; Aalekhya Sharma Biswas

Purpose Cervical cancer is the second most common cancer in India. Our study assessed the level and impact of awareness programs in the adoption of safe practices in prevention and early detection. Methods This assessment was part of a Pink Chain Campaign, the mission of which is to fight cancer. During cancer awareness events from 2013 to 2015 at various women’s colleges in different parts in India, a pretest related to cervical cancer was followed by an awareness program. A post-test was conducted 6 months and 1 year later. Results A total of 872 of 985 teachers participated in the study, for a response rate of 88.5%. Mean age of the population was 42.4 years. There was a significant increase in the level of knowledge regarding cervical cancer at 6 months, which was sustained at 1 year. Regarding cervical cancer screening, knowledge and practice of the Papanicolaou (Pap) test as a screening test for cervical cancer among teachers were changed significantly at 6 months and 1 year. More than 75% of teachers were educated by physicians about the Pap test. At the time of the post-test, there was a significant change in alcohol and smoking habits. The main reasons for not undergoing a screening test were ignorance (50%), lethargic attitude (44.8%), and lack of time (34.6%). Conclusion The level of knowledge of cervical cancer was poor. A significant increase in the level of knowledge of cervical cancer among the population was found after this study. To inculcate safe lifestyle practices, awareness programs should be conducted more widely and frequently.


Asian Pacific Journal of Cancer Prevention | 2018

Targeting Inflammation in Ovarian Cancer Through Natural Antioxidants, Potential Therapeutic and Preventive Implications

Mayank Singh; Abhishek Shankar; K S Dhiman; Rajesh Kotecha; Goura Kishor Rath

There is extensive experimental data to supportthe hypothesis that Reactive oxygen species (ROS)accumulation is one of the major underlying mechanismfor carcinogenesis. Many forms of cancer are associatedwith excessive accumulation of ROS including ovariancancer. It is now well understood that ROS productionshould be scavenged by antioxidant defence mechanism/DNA damage response of the human body to maintainnatural homeostasis (Kruk and Aboul-Enein, 2017).Dysregulation of this balance leads to many inflammatorydiseases including the high risk of developing cancer. HighROS concentration is associated with accumulation ofmutations which over the years leads to development ofcancer. Metabolic pathways including aerobic oxidationin mitochondria respiratory are the major source of ROSwhich in turn effect different signalling pathways (Krukand Aboul-Enein, 2017).


Asian Pacific Journal of Cancer Prevention | 2018

NCI Summer Curriculum in Cancer Control and Prevention – A Practice Changing Course for Oncologists from Limited Resource Country Like India

Abhishek Shankar; Rakesh Thakur; Nandu Meshram; Keduovinuo Keditsu; Priya Srinivas

Cancer has become an important public health issue in India. Oncologists in India spends most of their time in diagnosis and treatment of cancer patients. There is a large disparity geographically as far as cancer treatment facilities are concerned. Cancer control and cancer prevention is not a point of concern for most of the practicing oncologist. Although things are changing in India, but orientation, passion and dedication towards cancer prevention is still missing. There is no program on basic principles and practice of cancer control and prevention in India which addresses the essence of cancer control and prevention. Center for Global Health of National Cancer Institute, USA initiated summer curriculum is an excellent academic program to teach health care professionals working in cancer care in different parts of world. This covers all aspect of cancer care i.e. cancer education, epidemiology, screening, diagnosis, treatment and the before world palliative care with dedicated session on upcoming molecular prevention in cancer. This gives an unique opportunity for learning and can be practice changing curriculum for many of the attendees who want to pursue a career in cancer control and prevention a before practice.

Collaboration


Dive into the Abhishek Shankar's collaboration.

Top Co-Authors

Avatar

Goura Kishor Rath

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Abhidha Malik

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Vineet Kumar Kamal

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Abhijit Chakraborty

Physical Research Laboratory

View shared research outputs
Top Co-Authors

Avatar

Goura K. Rath

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Pramod Kumar Julka

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Aanchal Kakkar

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Menal Bhandari

All India Institute of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Narayan Adhikari

All India Institute of Medical Sciences

View shared research outputs
Researchain Logo
Decentralizing Knowledge